Wright C E, Sisson T L, Fleishaker J C, Antal E J
Clinical Pharmacokinetics Unit, Upjohn Company, Kalamazoo, Michigan 49001, USA.
J Clin Pharmacol. 1997 Apr;37(4):321-9. doi: 10.1002/j.1552-4604.1997.tb04309.x.
The relationship between the pharmacokinetics of alprazolam and dose and the relationship between the concentration of alprazolam and psychomotor performance in healthy male volunteers were investigated in this double-blind, placebo-controlled, modified crossover study. Twenty-four volunteers received placebo in Phase I and then received single 2-mg, 4-mg, 8-mg, and 10-mg doses of a sustained-release formulation in Phases II through V, according to, a crossover design. Blood samples were collected at several times throughout each phase to 48 hours after the dose; the harvested plasma was assayed for concentrations of alprazolam, 4-hydroxyalprazolam, and alpha-hydroxyalprazolam by high-performance liquid chromatography. Sedation was rated at each blood-sampling time and psychomotor performance tests, consisting of digit-symbol substitution and card-sorting tasks, were conducted at several times after each dose. Area under the concentration-time curve and peak concentration for alprazolam increased proportionally with each higher dose; clearance did not differ significantly between treatments. The concentrations of 4-hydroxyalprazolam and alpha-hydroxyalprazolam increased proportionally with dose and the combined plasma concentration of the metabolites were less than 15% of unchanged concentrations of alprazolam for all doses. Maximum sedation increased with each increase in dose up to 8 mg, and psychomotor performance decreased with each increase in dose. Performance versus concentration curves for alprazolam exhibited a clockwise hysteresis loop in contrast to the counterclockwise hystereses previously reported for both intravenous and oral doses of immediate-release tablets. Data through 6 hours after dose were well described by a sigmoid Emax model. Alprazolam exhibits linear pharmacokinetics after single oral doses of sustained-release tablets between 2 mg and 10 mg. Reversal of the concentration-effect curve to a clockwise loop suggests the counterclockwise hystereses of rapidly absorbed doses was caused by the differing distribution rates into the systemic circulation and effect site and not by metabolite activity.
在这项双盲、安慰剂对照、改良交叉研究中,对健康男性志愿者中阿普唑仑的药代动力学与剂量之间的关系以及阿普唑仑浓度与精神运动表现之间的关系进行了研究。24名志愿者在第一阶段接受安慰剂,然后在第二阶段至第五阶段根据交叉设计接受单剂量2毫克、4毫克、8毫克和10毫克的缓释制剂。在每个阶段的不同时间点直至给药后48小时采集血样;通过高效液相色谱法测定采集的血浆中阿普唑仑、4-羟基阿普唑仑和α-羟基阿普唑仑的浓度。在每次采血时对镇静程度进行评分,并在每次给药后的不同时间进行精神运动表现测试,包括数字符号替换和卡片分类任务。阿普唑仑的浓度-时间曲线下面积和峰浓度随剂量增加而成比例增加;各治疗组之间的清除率无显著差异。4-羟基阿普唑仑和α-羟基阿普唑仑的浓度随剂量成比例增加,且所有剂量下代谢物的血浆总浓度均低于阿普唑仑未变化浓度的15%。最大镇静程度随剂量增加至8毫克而增加,精神运动表现随剂量增加而下降。与先前报道的静脉注射和口服速释片的逆时针滞后现象相反,阿普唑仑的表现-浓度曲线呈现顺时针滞后环。给药后6小时的数据通过S形Emax模型得到了很好的描述。单次口服2毫克至10毫克缓释片后,阿普唑仑呈现线性药代动力学。浓度-效应曲线转变为顺时针环表明,快速吸收剂量的逆时针滞后现象是由进入体循环和效应部位的分布速率不同引起的,而非代谢物活性所致。